- Home
- AMZE vs GTBP Comparison
AMZE vs GTBP Comparison
Compare AMZE & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZE | GTBP |
|---|---|---|
| Founded | 2019 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 8.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMZE | GTBP |
|---|---|---|
| Price | $0.50 | $0.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 1.8M |
| Earning Date | 11-14-2025 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,245,143.00 | N/A |
| Revenue This Year | $6,741.66 | N/A |
| Revenue Next Year | $100.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 369.95 | N/A |
| 52 Week Low | $0.24 | $0.54 |
| 52 Week High | $19.44 | $3.85 |
Technical Indicators
Market Signals| Indicator | AMZE | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 48.74 |
| Support Level | $0.41 | $0.69 |
| Resistance Level | $0.70 | $0.74 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 41.88 | 63.21 |
Price Performance
Historical ComparisonAbout AMZE Amaze Holdings Inc.
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.